Thromboxane and the thromboxane receptor in cardiovascular disease.
Thromboxane and the thromboxane receptor in cardiovascular disease.
复制标题
DOI：
10.2217/clp.10.11
复制
发表时间：
2010-04-01
影响因子：
--
通讯作者：
Smyth EM
中科院分区：
文献类型：
--
作者：
Smyth EM
血栓烷A2（TXA 2）是花生四烯酸经考克斯-1依赖性代谢的主要产物，通过TXA 2受体（TP）介导其生物学作用。低剂量阿司匹林对血小板考克斯-1衍生的TXA 2的不可逆抑制提供了对原发性和继发性血管血栓形成事件的保护，强调了TXA 2作为血小板激动剂在心血管疾病中的中心作用。与阿司匹林使用相关的局限性包括显著的胃肠道毒性、出血并发症、潜在的个体间反应变异性和在某些疾病状态下的疗效差。这与TXA 2在血小板以外的心血管疾病中的广泛作用一起，使人们重新关注其他TXA 2相关药物靶点，特别是TXA 2合酶和TP。这些药物在临床疗效、耐受性和商业可行性方面优于低剂量阿司匹林，这仍然是一个悬而未决的问题，也是正在进行的研究的焦点。
Thromboxane A2 (TXA2), the primary product of COX-1-dependent metabolism of arachidonic acid, mediates its biological actions through the TXA2 receptor, termed the TP. Irreversible inhibition of platelet COX-1-derived TXA2 with low-dose aspirin affords protection against primary and secondary vascular thrombotic events, underscoring the central role of TXA2 as a platelet agonist in cardiovascular disease. The limitations associated with aspirin use include significant gastrointestinal toxicity, bleeding complications, potential interindividual response variability and poor efficacy in some disease states. This, together with the broad role of TXA2 in cardiovascular disease beyond the platelet, has refocused interest towards additional TXA2-associated drug targets, in particular TXA2 synthase and the TP. The superiority of these agents over low-dose aspirin, in terms of clinical efficacy, tolerability and commercial viability, remain open questions that are the focus of ongoing research.
登录
查看更多内容
影响因子：
37.8
作者：
Cipollone, F;Patrignani, P;Maseri, A
通讯作者：
Maseri, A
影响因子：
5.3
作者：
Cyrus, Tillmann;Ding, Tao;Pratico, Domenico
通讯作者：
Pratico, Domenico
影响因子：
5
作者：
Cyrus, Tillmann;Yao, Yuemang;Pratico, Domenico
通讯作者：
Pratico, Domenico
影响因子：
56.9
作者：
Cheng, Y;Austin, SC;FitzGerald, GA
通讯作者：
FitzGerald, GA
DOI：
10.1136/bmj.a1840
发表时间：
2008-10-16
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Belch J;MacCuish A;Campbell I;Cobbe S;Taylor R;Prescott R;Lee R;Bancroft J;MacEwan S;Shepherd J;Macfarlane P;Morris A;Jung R;Kelly C;Connacher A;Peden N;Jamieson A;Matthews D;Leese G;McKnight J;O'Brien I;Semple C;Petrie J;Gordon D;Pringle S;MacWalter R;Prevention of Progression of Arterial Disease and Diabetes Study Group;Diabetes Registry Group;Royal College of Physicians Edinburgh
通讯作者：
Royal College of Physicians Edinburgh